Drugs as P-glycoprotein substrates, inhibitors, and inducers

REFERENCES

• Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Biochemical, Cellular, and Pharmacological Aspects of the Multidrug Transporter. Annu. Rev. Pharmacol. Toxicol. 1999; 39: 361–398
   PubMed Web of Science ®Google Scholar
• Gottesman M.M., Hrycyna C.A., Schoenlein P.V., Germann U.A., Pastan I. Multidrug Resistance P-glycoprotein, Chemotherapy, Episomes, Gene, Therapy. Genetic Analysis of the Multidrug Transporter. Ann. Rev. Genet. 1995; 29: 607–649
   PubMed Web of Science ®Google Scholar
• Smit J.J., Schinkel A.H., Oude Elferink R.P.J., Groen A.K., Wagenaar E., van Deemter L., Mol C.A.A.M., Ottenhoff R., van der Lugt N.M.T., van Roon M.A., van der Valk M.A., Offerhaus G.J.A., Berns A.J.M., Borst P. Homozygous Disrupting of the Murine mdr2 P-Glycoprotein Gene Leads to a Complete Absence of Phospholipid from Bile and to Liver Disease. Cell 1993; 75: 451–462
   PubMed Web of Science ®Google Scholar
• Gottesman M.M., Pastan I. Biochemistry of Multidrug Resistance Mediated by the Multidrug Transporter. Ann. Rev. Biochem. 1993; 62: 385–427
   PubMed Web of Science ®Google Scholar
• Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular Localization of the Multidrug-Resistance Gene Product P-Glycoprotein in Normal Human Tissues. Proc. Natl Acad. Sci. 1987; 84: 7735–7738
   PubMed Web of Science ®Google Scholar
• Schinkel A.H. Pharmacological Insights from P-Glycoprotein Knockout Mice. Int. J. Clin. Pharmacol. Ther. 1998; 36: 9–13
   PubMed Web of Science ®Google Scholar
• Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J.J., Roden D.M., Wilkinson G.R. The Drug Transporter P-Glycoprotein Limits Oral Absorption and Brain Entry of HIV-1 Protease Inhibitors. J. Clin. Invest. 1998; 10: 289–294
   Web of Science ®Google Scholar
• Schinkel A.H. P-Glycoprotein, A Gatekeeper in the Blood–Brain Barrier. Adv. Drug Del. Rev. 2000; 36: 179–194
   Web of Science ®Google Scholar
• Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A.A.M., van der Valk M.A., Robanus-Maandag E.C., Riele H.P.J., Berns A.J.M., Borst P. Disruption of the Mouse mdr1a P-Glycoprotein Gene Leads to a Deficiency in the Blood–Brain Barrier and to Increased Sensitivity to Drugs. Cell 1994; 77: 491–502
   PubMed Web of Science ®Google Scholar
• Umbenhauer D.R., Lankas G.R., Pippert T.R., Wise L.D., Cartwright M.E., Hall S.J., Beare C.M. Identification of a P-Glycoprotein-Deficient Subpopulation in the CF-1 Mouse Strain Using a Restriction Fragment Length Polymorphism. Toxicol. Appl. Pharmacol. 1997; 146: 88–94
   PubMed Web of Science ®Google Scholar
• Schinkel A.H., Mayer U., Wagenaar E., Mol C.A., van Deemter L., Smit J.J., van der Valk M.A., Voordouw A.C., Spits H., van Tellingen O., Zijlmans J.M., Fibbe W.E., Borst P. Normal Viability and Altered Pharmacokinetics in Mice Lacking mdr1-type (Drug-Transporting) P-Glycoproteins. Proc. Natl Acad. Sci. 1997; 94: 4028–4033
   PubMed Web of Science ®Google Scholar
• Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A.A.M., Borst P. Absence of the mdr1a P-Glycoprotein in Mice Affects Tissue Distribution and Pharmacokinetics of Dexamethasone, Digoxin, and Cyclosporin A. J. Clin. Invest. 1995; 96: 1698–1705
   PubMed Web of Science ®Google Scholar
• Pippert T.R., Umbenhauer D.R. The Subpopulation of CF-1 Mice Deficient in P-Glycoprotein Contains a Murine Retroviral Insertion in the mdr1a Gene. J. Biochem. Mol. Toxicol. 2001; 15: 83–89
   PubMed Web of Science ®Google Scholar
• Kwei G.Y., Alvaro R.F., Chen Q., Jenkins H.J., Hop C.E., Keohane C.A., Ly V.T., Strauss J.R., Wang R.W., Wang Z., Pippert T.R., Umbenhauer D.R. Disposition of Ivermectin and Cyclosporin A in CF-1 Mice Deficient in mdr1a P-Glycoprotein. Drug Metab. Dispos. 1999; 27: 581–587
   PubMed Web of Science ®Google Scholar
• Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-Glycoprotein in the Blood–Brain Barrier of Mice Influences the Brain Penetration and Pharmacological Activity of Many Drugs. J. Clin. Invest. 1996; 97: 2517–2524
   PubMed Web of Science ®Google Scholar
• Lankas G.R., Wise L.D., Cartwright M.E., Pippert T., Umbenhauer D.R. Placental P-Glycoprotein Deficiency Enhances Susceptibility to Chemically Induced Birth Defects in Mice. Reprod. Toxicol. 1998; 12: 457–463
   PubMed Web of Science ®Google Scholar
• Smit J.W., Huisman M.T., van Tellingen O., Wiltshire H.R., Schinkel A.H. Absence or Pharmacological Blocking of Placental P-Glycoprotein Profoundly Increases Fetal Drug Exposure. J. Clin. Invest. 1999; 104: 1441–1447
   PubMed Web of Science ®Google Scholar
• Kim R.B., Wandel C., Leake B., Cvetkovic M., Fromm M.F., Dempsey P.J., Roden M.M., Belas F., Chaudhary A.K., Roden D.M., Wood A.J., Wilkinson G.R. Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein. Pharm. Res. 1999; 16: 408–414
   PubMed Web of Science ®Google Scholar
• Saeki T., Ueda K., Tanigawara Y., Hori R., Komano T. P-Glycoprotein-Mediated Transcellular Transport of MDR-Reversing Agents. FEBS Lett. 1993; 324: 99–102
   PubMed Web of Science ®Google Scholar
• Yusa K., Tsuruo T. Reversal Mechanism of Multidrug Resistance by Verapamil: Direct Binding of Verapamil to P-Glycoprotein on Specific Sites and Transport of Verapamil Outward Across the Plasma Membrane of K562/ADM Cells. Cancer Res. 1989; 49: 5002–5006
   PubMed Web of Science ®Google Scholar
• Ford J.M. Experimental Reversal of P-Glycoprotein-Mediated Multidrug Resistance by Pharmacological Chemosensitisers. Eur. J. Cancer 1996; 32A: 991–1001
   PubMed Web of Science ®Google Scholar
• Ferry D.R. Testing the role of P-Glycoprotein Expression in Clinical Trials—Applying Pharmacological Principles and Best Methods for Detection Together with Good Clinical Trials Methodology. Int. J. Clin. Pharmacol. Ther. 1998; 36: 29–40
   PubMed Web of Science ®Google Scholar
• Dantzig A.H., Law K.L., Starling J.J. Reversal of Multidrug Resistance by the P-Glycoprotein Modulator LY335979, from the Bench to the Clinic. Curr. Med. Chem. 2001; 8: 39–50
   PubMed Web of Science ®Google Scholar
• Schuetz E.G., Beck W.T., Schuetz J.D. Modulators and Substrates of P-Glycoprotein and Cytochrome P4503A Coordinately Up-Regulate These Proteins in Human Colon Carcinoma Cells. Mol. Pharmacol. 1996; 49: 311–318
   PubMed Web of Science ®Google Scholar
• Greiner B., Eichelbaum M., Fritz P., Kreichgauer H.P., von Richter O., Zundler J., Kroemer H.K. The Role of Intestinal P-Glycoprotein in the Interaction of Digoxin and Rifampin. J. Clin. Invest. 1999; 104: 147–153
   PubMed Web of Science ®Google Scholar
• Geick A., Eichelbaum M., Burk O. Nuclear Receptor Response Elements Mediate Induction of Intestinal mdr1 by Rifampin. J. Biol. Chem. 2001; 276: 14581–14587
   PubMed Web of Science ®Google Scholar
• Ueda K., Okamura N., Hirai M., Tanigawara Y., Saeki T., Kioka N., Komano T., Hori R. Human P-Glycoprotein Transports Cortisol, Aldosterone, and Dexamethasone, But Not Progesterone. J. Biol. Chem. 1992; 267: 24248–24252
   PubMed Web of Science ®Google Scholar
• Boyd R.A., Stern R.H., Stewart B.H., Wu X., Reyner E.L., Zegarac E.A., Randinitis E.J., Whitfield L. Atorvastatin Coadministration May Increase Digoxin Concentrations by Inhibition of Intestinal P-Glycoprotein-Mediated Secretion. J. Clin. Pharmacol. 2000; 40: 91–98
   PubMed Web of Science ®Google Scholar
• Perloff M.D., von Moltke L.L., Fahey J.M., Daily J.P., Greenblatt D.J. Induction of P-Glycoprotein Expression by HIV Protease Inhibitors in Cell Culture. AIDS 2000; 14: 1287–1289
   PubMed Web of Science ®Google Scholar
• Polli J.W., Jarrett J.L., Studenberg S.D., Humphreys J.E., Dennis S.W., Brouwer K.R., Woolley J.L. Role of P-Glycoprotein on the CNS Disposition of Amprenavir (141W94), an HIV Protease Inhibitor. Pharm. Res. 1999; 16: 1206–1212
   PubMed Web of Science ®Google Scholar
• Orlowski S., Valente D., Garrigos M., Ezan E. Bromocriptine Modulates P-Glycoprotein Function. Biochem. Biophys. Res. Commun. 1998; 244: 481–488
   PubMed Web of Science ®Google Scholar
• Watchko J.F., Daood M.J., Hansen T.W. Brain Bilirubin Content is Increased in P-Glycoprotein-Deficient Transgenic Null Mutant Mice. Pediatr. Res. 1998; 44: 763–766
   PubMed Web of Science ®Google Scholar
• Jonsson O., Behnam-Motlagh P., Persson M., Henriksson R., Grankvist K. Increase in Doxorubicin Cytotoxicity by Carvedilol Inhibition of P-Glycoprotein Activity. Biochem. Pharmacol. 1999; 58: 1801–1806
   PubMed Web of Science ®Google Scholar
• Lin J.H., Chiba M., Chen I.W., Nishime J.A., deLuna F.A., Yamazaki M., Lin Y.J. Effect of Dexamethasone on the Intestinal First-Pass Metabolism of Indinavir in Rats: Evidence of Cytochrome P-450 A and P-Glycoprotein Induction. Drug Metab. Dispos. 1999; 27: 1187–1193
   PubMed Web of Science ®Google Scholar
• Collett A., Higgs N.B., Sims E., Rowl M., Warhurst A. Modulation of the Permeability of H2 Receptor Antagonists Cimetidine and Ranitidine by P-Glycoprotein in Rat Intestine and the Human Colonic Cell Line caco-2. J. Pharmacol. Exp. Ther. 1999; 288: 171–178
   PubMed Web of Science ®Google Scholar
• Aquilante C.L., Letrent S.P., Pollack G.M., Brouwer K.L. Increased Brain P-Glycoprotein in Morphine Tolerant Rats. Life Sci. 2000; 66: L47–L51
   Web of Science ®Google Scholar
• Hyafil F., Vergely C., Du V.P., Grand-Perret T. In Vitro and In Vivo Reversal of Multidrug Resistance by GF120918, an Acridonecarboxamide Derivative. Cancer Res. 1993; 53: 4595–4602
   PubMed Web of Science ®Google Scholar
• Chu X.Y., Kato Y., Sugiyama Y. Possible Involvement of P-Glycoprotein in Biliary Excretion of CPT-11 in Rats. Drug Metab. Dispos. 1999; 27: 440–441
   PubMed Web of Science ®Google Scholar
• Takara K., Tanigawara Y., Komada F., Nishiguchi K., Sakaeda T., Okumura K. Cellular Pharmacokinetic Aspects of Reversal Effect of Itraconazole on P-Glycoprotein-Mediated Resistance of Anticancer Drugs. Biol. Pharm. Bull. 1999; 22: 1355–1359
   PubMed Web of Science ®Google Scholar
• Floren L.C., Bekersky I., Benet L.Z., Mekki Q., Dressler D., Lee J.W., Roberts J.P., Hebert M.F. Tacrolimus Oral Bioavailability Doubles with Coadministration of Ketoconazole. Clin. Pharmacol. Ther. 1997; 62: 41–49
   PubMed Web of Science ®Google Scholar
• Elhafny B., Chappey O., Piciotti M., Debray M., Boval B., Roux F. Modulation of P-Glycoprotein Activity by Glial Factors and Retinoic Acid in an Immortalized Rat Brain Microvessel Endothelial Cell Line. Neurosci. Lett. 1997; 236: 107–111
   PubMed Web of Science ®Google Scholar
• Dantzig A.H., Shepard R.L., Cao J., Law K.L., Ehlhardt W.J., Baughman T.M., Bumol T.F., Starling J.J. Reversal of P-Glycoprotein-Mediated Multidrug Resistance by a Potent Cyclopropyldibenzosuberane Modulator LY335979. Cancer Res. 1996; 56: 4171–4179
   PubMed Web of Science ®Google Scholar
• de Lannoy I.A., Silverman M. The MDR1 Gene Product P-Glycoprotein, Mediates the Transport of the Cardiac Glycoside, Digoxin. Biochem. Biophys. Res. Commun. 1992; 189: 551–557
   PubMed Web of Science ®Google Scholar
• Callaghan R., Riordan J.R. Synthetic and Natural Opiates Interact with P-Glycoprotein in Multidrug-Resistant Cells. J. Biol. Chem. 1993; 268: 16059–16064
   PubMed Web of Science ®Google Scholar
• Choo E.F., Leake B., Wandel C., Imamura H., Wood A.J., Wilkinson G.R., Kim R.B. Pharmacological Inhibition of P-Glycoprotein Transport Enhances the Distribution of HIV-1 Protease Inhibitors into Brain and Testes. Drug Metab. Dispos. 2000; 28: 655–660
   PubMed Web of Science ®Google Scholar
• Durr D., Stieger B., Kullak-Ublick G.A., Rentsch K.M., Steinert H.C., Meier P.J., Fattinger K. St John's Wort Induces Intestinal P-Glycoprotein/MDR1 and Intestinal and Hepatic CYP3A4. Clin. Pharmacol. Ther. 2000; 68: 598–604
   PubMed Web of Science ®Google Scholar
• Schuetz E.G., Yasuda K., Arimori K., Schuetz J.D. Human MDR1 and Mouse mdr1a P-Glycoprotein Alter the Cellular Retention and Disposition of Erythromycin, But Not of Retinoic Acid or Benzo(a)pyrene. Arch. Biochem. Biophys. 1998; 350: 340–347
   PubMed Web of Science ®Google Scholar
• Barnes K.M., Dickstein B., Cutler G.B.J., Fojo T., Bates S.E. Steroid Transport, Accumulation, and Antagonism of P-Glycoprotein in Multidrug-Resistant Cells. Biochemistry 1996; 35: 4820–4827
   PubMed Web of Science ®Google Scholar
• Huang L., Hoffman T., Vore M. Adenosine Triphosphate-Dependent Transport of Estradiol-17beta(Beta-d-Glucuronide) in Membrane Vesicles by MDR1 Expressed in Insect Cells. Hepatology 1998; 28: 1371–1377
   PubMed Web of Science ®Google Scholar
• Cvetkovic M., Leake B., Fromm M.F., Wilkinson G.R., Kim R.B. OATP and P-Glycoprotein Transporters Mediate the Cellular Uptake and Excretion of Fexofenadine. Drug Metab. Dispos. 1999; 27: 866–871
   PubMed Web of Science ®Google Scholar
• Miyama T., Takanaga H., Matsuo H., Yamano K., Yamamoto K., Iga T., Naito M., Tsfuruo T., Ishizuka H., Kawahara Y., Sawada Y. P-Glycoprotein-Mediated Transport of Itraconazole Across the Blood–Brain Barrier. Antimicrob. Agents Chemother. 1998; 42: 1738–1744
   PubMed Web of Science ®Google Scholar
• Didier A.D., Loor F. Decreased Biotolerability for Ivermectin and Cyclosporin A in Mice Exposed to Potent P-Glycoprotein Inhibitors. Int. J. Cancer 1995; 63: 263–267
   PubMed Web of Science ®Google Scholar
• Saitoh H., Hatakeyama M., Eguchi O., Oda M., Takada M. Involvement of Intestinal P-Glycoprotein in the Restricted Absorption of Methylprednisolone from Rat Small Intestine. J. Pharmaceut. Sci. 1998; 87: 73–75
   PubMed Web of Science ®Google Scholar
• Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K., Borst P., Nooijen W.J., Beijnen J.H., van Tellingen O. Limited Oral Bioavailability and Active Epithelial Excretion of Paclitaxel (Taxol) Caused by P-Glycoprotein in the Intestine. Proc. Natl Acad. Sci. 1997; 94: 2031–2035
   PubMed Web of Science ®Google Scholar
• Kavallaris M., Madagiflio J., Norris M.D., Haber M. Resistance to Tetracycline, a Hydrophilic Antibiotic Is Mediated by P-Glycoprotein in Human Multidrug-Resistant Cells. Biochem. Biophys. Res. Commun. 1993; 190: 79–85
   PubMed Web of Science ®Google Scholar
• Smit J.W., Schinkel A.H., Muller M., Weert B., Meijer D.K. Contribution of the Murine mdr1a P-Glycoprotein to Hepatobiliary and Intestinal Elimination of Cationic Drugs as Measured in Mice with an mdr1a Gene Disruption. Hepatology 1998; 27: 1056–1063
   PubMed Web of Science ®Google Scholar
• Cormet-Boyaka E., Huneau J.F., Boyaka P.N., Carbon C., Rubinstein E., Tome D. Secretion of Sparfloxacin from the Human Intestinal Caco-2 Cell Line Is Altered by P-Glycoprotein Inhibitors. Antimicrob. Agents Chemother. 1998; 2607–2611
   PubMed Web of Science ®Google Scholar